Log in to save to my catalogue

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_03732372v1

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Lanifibranor is a pan–peroxisome proliferator–activated receptor agonist that modulates metabolic and inflammatory pathways. In this 24-week, phase 2b, placebo-controlled trial involving patients with NASH, 1200 mg of lanifibranor, but not 800 mg, significantly improved histologic features of NASH. Weight gain, anemia, peripheral edema, diarrhea, a...

Alternative Titles

Full title

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_03732372v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_03732372v1

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2036205

How to access this item